An investigational vaccine designed by researchers at the Washington University (WashU) School of Medicine to prevent tumor recurrence has shown promising results in a phase I trial among patients with triple-negative breast cancer (TNBC). The neoantigen DNA vaccine targets patient-specific cancer neoantigens—mutant proteins or amino acid sequences that arise from…

Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a computational method to assess which patients with metastatic triple-negative breast cancer could benefit from immunotherapy. The work, published in the Proceedings of the National Academy of Sciences, aims to develop a more…

Triple-negative breast cancer (TNBC), the most aggressive and difficult-to-treat form of breast cancer, may soon have a new treatment option. Researchers from the Brigham and Women’s Hospital, part of the Mass General Brigham healthcare system, have identified a promising therapeutic strategy that combines two types of drugs, setting the stage…

A recent study by researchers at the Baylor College of Medicine has shed light on the role of DAPK3 in triple-negative breast cancer (TNBC), detailing its regulation of epithelial-mesenchymal transition (EMT) which is a process linked to cancer metastasis. This research, published in the journal PNAS Nexus, provides a better…

Researchers at the Centre for Genomic Regulation and Vall d’Hebron Institute of Oncology, both in Barcelona, Spain, indicate that simultaneously inhibiting two specific proteins could slow the growth of triple-negative breast cancer (TNBC). The study, which appears in the journal EMBO Molecular Medicine, could have siginficant implications for this hard…

A team of researchers at Baylor College of Medicine—and collaborating institutions—have discovered in animal model testing that Zotatifin a drug targeting the elF4A protein suppressed tumor cell proliferation and remodeled the tumor immune microenvironment and could be a key to treating triple-negative breast cancer (TNBC). The findings, reported in The…

A team of investigators at Vanderbilt-Ingram Cancer Center, reporting in Cancer Discovery, has discovered a druggable target on natural killer cells that could create a therapeutic response in patients with immunotherapy-resistant triple-negative breast cancer. While immunotherapy has shown promise across a range of cancers and tumor types, only about 15%…

Moffit Cancer Center researchers have reported in Nature Medicine that use of an oncolytic virus treatment in combination with chemotherapy can boost response rates during neoadjuvant therapy for triple-negative breast cancer (TNBC). The modified oncolytic herpes simplex 1 virus—talimogene laherparepvec (T-VEC)—is already approved to treat advanced melanoma. It is injected…

In triple-negative breast cancer (TNBC), tumors express molecular markers of the epithelial-mesenchymal transition (EMT)—during which cells acquire the ability to move and migrate. Now, a new study from researchers at the the Johns Hopkins Kimmel Cancer Center has revealed an important role played by EMT programs in TNBC metastasis. This…

Inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing, a new study by researchers at Yale Cancer Center shows. The discovery could be an early step in finding new therapeutics for this type of cancer, a very difficult disease to treat. The findings are published this…

A significant association between statins and survival rates of triple-negative breast cancer (TNBC) patients has been found by researchers from The University of Texas MD Anderson Cancer Center. Their study suggests that since statins are low in cost, easy to access, and produce minimal side effects, these drugs could have…

Researchers at the University of Virginia Cancer Center have identified a gene that is responsible for the spread of triple-negative breast cancer (TNBC) to other parts of the body, and which can render the cancer resistant to chemotherapy. Sanchita Bhatnagar, PhD, and her team have also developed a nanoparticle-delivered antibody…

In a new study of triple-negative breast cancer, scientists from the Princess Margaret Cancer Centre in Toronto and led by senior scientists Cheryl Arrowsmith, Ph.D., and Mathieu Lupien, Ph.D., reported they have found a promising approach with a protein biomarker that may potentially identify patients for more precise targeted therapy.…

A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers in the U.S., Taiwan, and China carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that…

U.K. researchers have repurposed algorithms that astrophysicists employ to discover black holes to create a digital twin model that can accurately predict treatment responses for different chemotherapy drug classes in people with cancer. The technology, called FarrSight®-Twin, could “help health professionals to match individuals to the right chemotherapy drug,” said…